AstraZeneca pays $1.2B to partner on CSPC obesity & diabetes meds

AstraZeneca's deal with CSPC Pharmaceutical Group includes a Phase 1-ready obesity drug that hits the same targets as Eli Lilly's obesity drug Zepbound, but with monthly dosing. The new collaboration builds on an existing drug R&D relationship between the two companies.

Editor's Pick

Top Story AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds AstraZeneca's deal with CSPC Pharmaceutical Group includes a Phase 1-ready obesity drug that hits the same targets as Eli Lilly's obesity drug Zepbound, but with monthly dosing. The new collaboration builds on an existing drug R&D relationship between the two companies. Sponsored How Can AI Support Dental Service Organizations? Presented by Overjet There is a growing demand for advanced technology integration, such as AI tools for clinical decision support, for example, to improve patient care and DSO efficiency.  Get insights on how DSO can benefit with Overjet's AI applications. Click here to learn more.

Featured News

Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs January has seen a slew of executive hires, promotions and layoffs across the healthcare industry. For instance, Aidoc, Suki and Particle Health named new executives. There were also layoffs at organizations including Takeda, Trinity Health and Horizon BCBS New Jersey. 4 Notable Health Tech Funding Announcements in January Health tech companies made several major funding announcements in January. Here is a list of some of the biggest funding rounds. Harnessing Clinical Expertise to Unlock Hospital Capacity The true foundation of capacity isn't only laid with steel and glass; it's also built through investment in platforms and processes, and benchmarks that prevent those beds from being needed in the first place. Humanized AI: No Longer Optional for Digital Patient Engagement The opportunity ahead is significant. Humanized AI can close the gaps that lead to disengagement, improve outcomes through proactive communication, and give providers the bandwidth to focus where they're needed most.

Video   Video: Inside a New Recursion Drug Katie Couric lost her husband to colon cancer in 1998. Nearly 30 years later, colon cancer rates are rising sharply, especially among younger people, and scientists still don't fully understand why. Watch Couric chat with Najat Khan, CEO of Recursion Pharmaceuticals. Recursion is using AI to identify a promising compound that targets the underlying biology of the disease.

Sponsored Omaha ABA Therapy: Comparing the Top Providers Presented by Stride Autism Centers The right provider enables children to gain confidence, learn to express their needs and discover new ways to connect with the world around them. Learn More

Resources

sponsored Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health Presented by Esperion In a recent interview, Esperion President and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company's expansion into new diseases. Read more

MedCity News • PO Box 901 • New York, NY unsubscribe